The global kidney cancer market is anticipated to grow at a substantial CAGR of 6.2% during the forecast period. Global kidney cancer is one of the most common cancers across the globe. Most kidney cancers get diagnosed before they metastasize to distant organs. However, the tumours can grow to be quite large before they are detected. The growth of the market is attributed to the increasing incidence of kidney cancers and increasing ill lifestyle changes which gets worsen with addiction to tobacco and alcohol. Furthermore, overexposure to radiation during treatment of testicular cancer, growing awareness programs, and increased mortality due to kidney cancer are boosting the kidney cancer market. For instance, in May 2019, Merck KGaA, Darmstadt, Germany, which operates its biopharmaceutical business as EMD Serono in the US and Canada, and Pfizer Inc. announced that the US Food and Drug Administration (FDA) has approved BAVENCIO (avelumab) in combination with INLYTA (axitinib) for the first-line treatment of patients with advanced renal cell carcinoma (RCC). This is the first FDA approval for an anti-PD-L1 therapy as part of a combination regimen for patients with advanced RCC.

However, the high cost associated with the treatment is the major restrain to the market. Generally, kidney cancer can cause in the range of $15,000 to $75,000. Various companies are getting FDA approval for kidney cancer and many drugs are in a clinical trial for the same. Hence innovation in drug development, and subsequent technological advancements & pipeline product finds an immense opportunity in near future.

Impact of COVID-19 Pandemic on Global Kidney Cancer Market

The global kidney cancer market has been adversely impacted by the sudden emergence of the COVID-19 infection due to the halt in diagnostic procedures and surgical procedures. Moreover, kidney cancer patients were more susceptible to COVID-19 infections than compared to an individual without cancer, as they were in an immunosuppressive state caused by the malignancy and anticancer treatment. There was a significant decrease in kidney cancer drugs and diagnosis rates globally. That had shown a negative impact for that short period.

Segmental Outlook 

The global kidney cancer market is segmented based on the cancer type, cancer cell, diagnosis, and therapy. Based on the cancer type, the market is segmented into renal cell carcinoma (RCC), transitional cell cancer, Wilm's tumor (nephroblastoma), and others. Based on the cancer cell, the market is sub-segmented into a clear cell, papillary, and other. Based on the diagnosis, the market is sub-segmented into biopsy, computed tomography (CT) scan, magnetic resonance imaging (MRI), and ultrasound. Based on therapy, the market is sub-segmented into surgery, immunotherapy, chemotherapy, radiation therapy, and cryotherapy.

Global Kidney Cancer Market Share by Cancer Type, 2021 (%)

The Renal Cell Carcinoma Segment is Expected to Hold Considerable Share in the Global Kidney Cancer Market

Renal cell cancer is a disease in which malignant (cancer) cells form in tubules of the kidney. Smoking and misuse of certain pain medicines can affect the risk of renal cell cancer. Symptoms of renal cell cancer include blood in the urine and a lump in the abdomen. According to the US Department of Health & Human Services, every year, more than 41,000 men and 24,000 women get kidney and renal pelvis cancers, and about 9,000 men and 5,000 women die from these diseases.

Regional Outlooks

The global kidney cancer market is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East &Africa, and Latin America).  The market can be analyzed for a particular region or country level as per the requirement. Europe is expected to dominate the global kidney cancer market owing to the high prevalence of kidney cancer in the UK, France, Germany, and other EU countries. The high prevalence of kidney cancer and high consumption of alcohol and tobacco are the major factor driving the market.

Global Kidney Cancer Market Growth, by Region 2022-2028

The North America Region is Expected to Hold a Considerable Share in the Global Kidney Cancer Market

The North American region is expected to have a major market share during the forecast period. In North America, the US and Canada are expected to have a major market share in the region. The American Cancer Society’s most recent estimates for kidney cancer in the US for 2022 are about 79,000 new cases of kidney cancer (50,290 in men and 28,710 in women) will be diagnosed and about 13,920 people (8,960 men and 4,960 women) will die from this disease.

Market Players Outlook

The major companies serving the global kidney cancer market include Abbvie Inc., Bayer Pharma AG, Merck & Co., GlaxoSmithKline Plc, and Pfizer Inc. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, For instance, in December 2021, BDR Pharma launched a standard type of Pazopanib to the Indian market and the drug is used to treat advanced renal cell carcinoma and soft tissue sarcoma.

The Report Covers

• Market value data analysis of 2021 and forecast to 2028.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global kidney cancer market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.